Prospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Oct 14, 2017; 23(38): 7037-7046
Published online Oct 14, 2017. doi: 10.3748/wjg.v23.i38.7037
Table 1 Description of the study population n (%)
Total (n = 1215)Follow-up contact
P value
Reply (n = 902)No reply (n = 313)
Male702 (57.8)511 (56.7)191 (61.0)0.18
Age (yr), mean ± SD36 ± 1537 ± 1534 ± 140.02
HBV prevalence of birth country< 0.001
Low (< 2.0%)670 (55.1)527 (58.4)143 (45.7)
Intermediate (2.0%-8.0%)331 (27.2)222 (24.6)109 (34.8)
High (> 8.0%)214 (17.6)153 (17.0)61 (19.5)
Parents from high endemic region276 (22.7)205 (22.7)71 (22.7)0.9
Traveled to high endemic region1284 (23.4)204 (22.6)80 (25.6)0.3
Healthcare in high endemic region177 (14.6)124 (13.8)53 (16.9)0.17
Health insurance plan< 0.001
Social security/CMU2913 (75.2)719 (79.7)194 (62.0)
CMUc361 (5.0)47 (5.2)14 (4.5)
AME4/Other/ None241 (19.8)136 (15.1)105 (33.6)
Received transfusion48 (4.0)33 (3.7)15 (4.8)0.4
Received tattoos151 (12.4)100 (11.1)51 (16.3)0.02
Received piercing510 (42.0)387 (42.9)123 (39.3)0.3
Close contact with HBV+ individual75 (6.2)57 (6.4)18 (5.8)0.7
Number of life-time sexual partners0.001
0-1181 (14.9)118 (13.1)63 (20.1)
2-9560 (46.1)409 (45.3)151 (48.2)
≥ 10474 (39.0)375 (41.6)99 (31.6)
> 1 sexual partner within 12 mo593 (48.8)447 (49.6)146 (46.7)0.4
Men who have sex with men93 (8.9)73 (8.1)20 (6.4)0.3
Nasal drug-use145 (11.9)108 (12.0)37 (11.8)0.9
Intravenous drug-use5 (0.4)5 (0.6)00.3
Long-term stay at a medical center50 (4.1)38 (4.2)12 (3.8)0.8
Previously incarcerated87 (7.2)63 (7.0)24 (7.7)0.7